Dr. Cotter presents several emerging technological innovations in dermatology aimed at enhancing the management of moles and melanoma. First, he discusses an AI-augmented handheld tool that uses painless electrical impedance spectroscopy to measure skin lesion resistance and risk-stratify atypical moles. Next, he details how a 31-gene expression profile test helps identify metastasis risk in low-risk thin tumors and guides sentinel lymph node biopsy decisions for intermediate-stage patients. Finally, he highlights the emerging use of circulating tumor DNA as a liquid biopsy method to monitor high-risk skin cancers, detect potential recurrences earlier than traditional radiographs, and predict response to therapies.
